ST Cube Advances Clinical Trial Combining Immune Checkpoint Inhibitors and Radiation Therapy

[Asia Economy Reporter Kum Bo-ryeong] STCube is advancing clinical trials combining immune checkpoint inhibitors with radiation therapy.

STCube announced on the 19th that it is promoting clinical trials combining the immune checkpoint inhibitor antibody 'STT-003' with radiation therapy in collaboration with researchers from the MD Anderson Cancer Center.

STT-003 is an immune checkpoint molecule discovered during joint research between STCube and the MD Anderson Cancer Center. Clinical trials are planned in the United States to develop it as an anticancer treatment.

An STCube official explained, "This is separate from the clinical trials being conducted as monotherapy," adding, "We are preparing clinical trials to verify the efficacy of combination therapy targeting patients for whom radiation therapy is essential, such as those with lung cancer, esophageal cancer, and head and neck cancer."

He continued, "In animal model studies for lung cancer, the tumor growth inhibition effect was compared among three groups. The group treated with combination therapy showed significantly suppressed tumor growth compared to the group treated with a single method," adding, "We plan to find the optimal clinical trial conditions through various future studies."

This content was produced with the assistance of AI translation services.